Singletto
Singletto develops and licenses Oxafence Active Protection, a materials-applied antimicrobial technology designed to integrate into existing products and manufacturing processes. Its platform enables ongoing antimicrobial performance within materials for healthcare, military, industry, and consumer applications, addressing environments where microbial exposure accumulates. The organization aims to unlock new capabilities in antimicrobial materials by partnering with manufacturers and researchers.
Facts
- HQ
- Seattle, US
- Sectors
- Biotechnology
- Founded
- 2020
- Type
- Corporation Seattle business license
- Employees
- 10
- Registered name
- Singletto Inc Seattle business license
- Stage
- Series A
- Members see funding amounts. .
- Founders
- James (Jim) Chen, MD, Thomas (Tom) Lendvay, MD
Is this your organization? Claim it
Seattle Startup Singletto Launches FDA-Approved Virus-Killing Masks on Amazon Following $10M Funding and DARPA Support
Seattle startup Singletto, with $10 million in funding and support from DARPA, has launched FDA-approved virus-neutralizing face masks on Amazon using its Oxafence Active Protection technology that kills 99.9% of certain viruses. The masks are the only FDA-cleared products in the U.S. that inactivate tested viruses and may have applications in healthcare and national security.
Seattle Startup Singletto Gains FDA Approval for Virus-Killing Oxafence Surgical Masks
Seattle startup Singletto received FDA approval for its Oxafence technology, a methylene blue-treated surgical mask that kills 99.9% of certain viruses within five minutes. The masks are already in use in New Zealand and represent a significant advancement over traditional masks by actively inactivating pathogens.
People
-
John Bjornson Executive Officer, Director, Co-Founder and Chief Executive Officer
-
Thomas Lendvay Executive Officer, Director, Co-Founder and Chief Medical Officer
-
James Chen Executive, Chief Scientific Officer